We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 7,120

Inherent Disclosure Supports Priority Claim
  • Foley & Lardner LLP
  • USA
  • September 28 2016

In Yeda Research and Development Co. v. Abbott GmbH and Co., the Federal Circuit invoked the doctrine of inherent disclosure to uphold a priority


Once Again, Written Description Does Not Limit Claim Scope
  • McDermott Will & Emery
  • USA
  • September 28 2016

Addressing the interplay between the written description and claim construction, the US Court of Appeals for the Federal Circuit reversed the district


Nanomedicine: A Vast Horizon on a Molecular Landscape - Part VI, Nanoparticles as Cancer Biomarkers
  • Dilworth IP
  • USA
  • September 27 2016

This is the sixth article in a review series on Nanomedicine. In Part I and Part II, we reviewed the major research and entrepreneurial development


Humira Biosimilar Approved As Litigation Gets Going
  • Patterson Belknap Webb & Tyler LLP
  • USA
  • September 26 2016

The FDA on Friday approved the first U.S. biosimilar of Humira (adalimumab), AbbVie’s best-selling biologic for treatment of inflammatory conditions


Trainees take on business: the Referendum Series
  • RPC
  • European Union, United Kingdom
  • September 23 2016

Never afraid to shy away from the most challenging of topics, in May of this year - with the EU Referendum vote looming - the blog’s Editorial Team


Searching for Causation in ACTOS Complaint
  • Patterson Belknap Webb & Tyler LLP
  • USA
  • September 23 2016

How explicitly must a complaint sounding in antitrust allege causation? At oral argument last week, the Court of Appeals for the Second Circuit


Double Patenting Decision Delivers Bitter Pill To Antibody Patent
  • Proskauer Rose LLP
  • USA
  • September 23 2016

In a recent decision on obviousness-type double patenting, Judge Wolf shortened the shelf life of a dispute between Janssen Biotech, Inc. (“Janssen”


Claim For Section 8 Damages Struck But Novel Cause Of Action Survives In Ontario Suit Re: Viagra Patent
  • McCarthy Tétrault LLP
  • Canada
  • September 22 2016

In this decision (2016 ONSC 4966), the Ontario Court dismissed Apotex’s claim for damages under s. 8 of the NOC Regulations in the face of a motion to


Stop them in their tracks: key points in seeking a preliminary injunction against medical device infringers
  • DLA Piper LLP
  • USA
  • September 22 2016

In 2006, the US Supreme Court reversed years of jurisprudence by eliminating the presumption of irreparable harm in patent litigations, which


Allegations Against Canadian Tenofovir Patent Found Unjustified (Again)
  • McCarthy Tétrault LLP
  • Canada
  • September 22 2016

Gilead’s Canadian Patent 2,261,619 (the “619 Patent”)the compound patent for tenofovir disoproxil fumarate (“TDF”)is no stranger to Canadian courts